Background: The reasons for variation in survival in breast cancer are multifactorial. Methods: From 1999 to 2003, the vital status of 9051 cases of invasive breast cancer was identified in the Eastern Region of England. Survival analysis was by Cox proportional hazards regression. Data were analysed separately for patients aged <70 years and those older due to differences in treatment policies.
introduction
The recent decrease in breast cancer deaths in the UK [1] has been attributed to early diagnosis and improvement in breast cancer treatment. Data, however, indicate discrepancies in breast cancer survival between regions and countries in Europe [2] . The major determinants of survival in breast cancer are pathological tumour size, lymph node status and histological grade [3] . Randomised trials have shown reduced fatality with hormonal treatment [in estrogen receptor (ER)-positive tumours] and cytotoxic and other systemic therapies [4, 5] . Trials of mammographic screening have shown reduced mortality in association with early detection [6] . In terms of results by treatment centre, higher survival has been observed in association with increased specialisation and a high-volume caseload [7] [8] [9] . In addition, lower survival tends to be observed in groups of low socio-economic status [10, 11] . It is not clear however whether the poorer survival in low socio-economic status groups is due to later stage at presentation, innate disease severity, co-morbidity or disparities in treatment.
Standardisation of care has been attempted in England by the introduction of Regional Cancer Networks and in Scotland by the Clinical Standards Board. Both strategies were adopted to ensure maximal adoption of national guidelines and reduce any geographical variation in outcome.
In this study, we examine survival with up to 109 months follow-up in 10 National Health Service (NHS) hospitals in the Eastern Region of England, all reporting to the Eastern Cancer Registration and Information Centre (ECRIC). We describe differences in outcomes between hospitals and seek to identify factors which explain these differences. We examine host factors (age and socio-economic status), tumour attributes (pathological size, node status and histological grade), hospital volume of breast cancer patients and treatment factors (type of surgery, radiotherapy, chemotherapy and hormone therapy) in relation to patient outcome. 6 months earlier, to allow for any delay in reporting of vital status. ECRIC actively followed up the vital status of each individual patient in this study in late 2008 by querying the National Health Service Strategic Tracing Service, so it is expected that these data are substantially complete and reliable. Data elements recorded by ECRIC include hospital of diagnosis, age at diagnosis, pathological tumour size, number of nodes excised and status, ER status, treatment type (wide local excision, mastectomy, axillary surgery, radiotherapy, chemotherapy, hormone therapy), mode of detection (screen detected or symptomatic) and Index of Multiple Deprivation (IMD) based on patients' electoral ward of residence. The primary sources of registration and treatment data are reports from all pathology laboratories and hospital patient notes which are viewed by registry staff who are either based at all major NHS hospitals in the region or visit them on at least a monthly basis. Both electronic and paper-based reports are received by the registry, so a high level of completeness of registration is also expected.
From the tumour size, lymph node status and histological grade, we calculated the Nottingham Prognostic Index (NPI) [12] for each case. The NPI has been validated in other breast cancer populations and allows assessment of the effect of different treatments in each of the five different prognostic groups, excellent (NPI £ 2.4), very good (2.4 < NPI £ 3.4), moderate 1 (3.4 < NPI £ 4.4), moderate 2 (4.4 < NPI £ 5.4) and poor (NPI > 5.4) [13] . Each tumour in the study was also staged by the fourth author (CHB) using the condensed tumour-node-metastasis system [14] . Analyses of outcomes were restricted to the 10 main NHS hospitals in the area studied; between 448 and 2051 cases were diagnosed at each of these hospitals during the 6-year period, while no other hospital in the area diagnosed >200 cases.
statistical analysis
We analysed the data for patients aged <70 years and patients aged ‡70 separately due to perceived differences in treatment policies in these age groups during the study period. Survival analysis used overall survival (OS) as the end point and was carried out using Cox proportional hazards regression, accompanied by life table estimates of survival probabilities by time [15] . Thereafter, analysis was aimed at identifying and describing differences in survival between institutions, attempting to attribute these to patient volume by hospital, case mix and treatment factors. The latter was carried out by adjusting for volume, tumour, host and treatment factors to ascertain whether adjustment for particular factors accounted for inter-hospital differences (i.e. after adjustment for which factors do the inter-hospital differences lose their statistical significance) and by subgroup analyses, identifying the predictors of survival in different groups of patients, such as node-negative and node-positive patients separately.
results patients aged <70 years Table 1 shows the number of patients and deaths by hospital and by patient and tumour attributes. Data were available on a total of 6106 patients aged <70 at diagnosis. Significant differences in survival were observed among the 10 hospitals (P = 0.03). Table 2 shows the relative hazards by hospital from the Cox regression analysis for hospital, node status and detection mode, unadjusted in univariate analyses and mutually adjusted in a multivariate analysis. From the survival rates in Table 1 , and the unadjusted relative hazards of death in Table 2 , hospitals 2 and 7-10 have poorer survival than the others. The differences lost their formal significance after adjustment for detection mode and node status, although the result remained close to statistical significance (P = 0.07) with some residual differences between the relative hazards, notably increased risks for hospitals 7-10, as can be seen in the adjusted relative hazards in Table 2 .
The observation that the inter-hospital survival differences are partially attributable to node status, including nodes not examined, is consistent with a highly significant (P = 0.008) negative ecological correlation between the proportion with nodes positive or not examined and the 9-year survival rates. The institutions with larger proportions node positive or nodes not examined have considerably lower survival (see Figure 1 ).
The inter-hospital survival differences were manifested in both early and late survival. Significant differences were observed both for survival up to 2 years after diagnosis and after 2 years (P = 0.02 in both cases), although the magnitude of the differences was greater after 2 years (data available from the authors). From Table 1 , it can be seen that the original article Annals of Oncology hospitals with better survival at 5 years also had better survival at 9 years. The inter-hospital survival differences were complicated by significant heterogeneity of the differences by node status categories (P = 0.01). Table 3 shows the relative hazards by hospital for the four node status categories separately. The inter-hospital differences in survival were not significant for node-negative cases but were significant for those with 1-3 nodes positive and those with nodes not examined. For cases with four or more nodes positive, the differences were of borderline significance. For 1-3 node-positive cases, the poorest survival was observed in hospitals 2, 8 and 9. For four or more nodes positive, the poorest survival was observed in hospitals 7 and 9, and in those with nodes not examined, the poorest survival was noted in hospitals 3 and 10.
Further multivariate survival analysis indicated that the differences between hospitals for those with 1-3 nodes positive were mainly due to differences between institutions in ER status and socio-economic status as measured by the IMD. Table 4 shows the inter-hospital relative hazards in this group, Figure 1 . Nine-year survival by percentage of cases node positive or with nodes not examined in the 10 hospitals, patients aged <70 years. unadjusted and adjusted for ER status and IMD. In addition to the attenuation of the inter-hospital differences after adjustment for ER status and IMD, it is also worth noting that those with ER status unknown are at significantly higher risk of dying than the ER-positive subjects and that there is a clear trend of increasing hazard of dying with increasing deprivation. For those with four or more nodes positive, the differences were not formally significant, but such differences in survival as were observed between hospitals were greater in women under age 50, i.e. below the age limit for screening. These did not seem to be attributable to hospital patient volume, host, tumour or treatment factors. Within the screening age range, survival was very similar for all hospitals. For those with nodes not examined, no host, tumour or treatment factors could be found which accounted for the inter-hospital differences.
In relation to the above it should be noted that for all node status groups, the survival differences between hospitals were larger for patients aged <50 years than for those with patients aged 50-69 years. Table 5 shows the significance of interhospital differences and the range of 5-year survival rates by node status, for the ages <50 and 50-69 separately. For all node status groups, the variation in survival between hospitals is considerably wider in the younger age group.
patients aged ‡70 years Data were available on 2945 patients aged ‡70 years. Numbers of patients and survival rates by hospital, IMD and tumour attributes are given in Table 6 . The variation in survival rates between hospitals was of significance (P = 0.05) and was further complicated by significant heterogeneity of the interhospital differences between those 2156 patients who had primary surgery and the 789 who did not (P < 0.001). Table 7 shows the numbers having primary surgery and 5-year survival rates by hospital for the two treatment groups. Significant differences in survival were observed among hospitals for both those who received surgery (P = 0.03) and those who did not (P < 0.001).
Among those receiving surgery, the inter-hospital differences in survival were partly attributable to age, ER status and hormonal therapy but not to any other factors. Table 8 shows the Cox regression relative hazards unadjusted and adjusted for age, ER status and hormonal therapy. After adjustment, the inter-hospital differences in survival were no longer significant.
Among those not receiving surgery, pathological factors were not available. Of the patient, hospital and treatment attributes, the only factor which partly accounted for the differences among hospitals was the proportion receiving hormone therapy. After adjustment for the proportion of patients aged ‡70 treated with hormone therapy, the survival differences were of borderline significance (P = 0.07).
discussion
Despite the overall 5-year survival rate of 78% for the whole group being good when compared with the rest of Europe, the above results show significant differences between 10 major treatment centres in the Eastern Region of England with respect to OS of breast cancer patients. These differences in women <70 years at diagnosis just lost significance when adjusted for node status and detection mode (screen detected Table 6 . Breast cancer cases and deaths by hospital, and by patient and tumour attributes, in patients aged ‡70 at diagnosis or symptomatic) and revealed four hospitals with increased risks (relative hazards 1.37-1.59, P = 0.07). We have recently shown that the mode of detection does impact on breast cancer survival [16] and should therefore be adjusted for in any inter-hospital comparison. Furthermore, not only is node positivity in this group associated with worse 9-year survival, the same negative correlation exists for nodes not examined. Survival differences in women aged ‡70 years were related to whether surgery was included as part of the treatment regimen in this age group. Overall, women in this age group who underwent surgery did better than those who did not. In addition, the hospitals in which a higher proportion of these older patients had surgery were characterised by better OS in patients aged >70 as a whole. Significant inter-hospital survival differences were found both for survival up to 2 years after diagnosis and after 2 years. At 9 years follow-up, survival rates ranged from 71% to 84%, an absolute difference of 13%. The inter-hospital differences in survival were significant for two node status groups: those with 1-3 nodes positive and those with nodes not examined. It is likely that differences in selection of systemic therapy in the 1-3 node-positive group (between hospitals) may partly explain these differences and that understaging of axillary nodes leads to inadequate systemic therapy.
In our data, other variables such as tumour size, histological grade and NPI were also associated with survival, as one would expect. We have not reported on these as our focus was to identify factors which explained the survival difference between institutions. In addition to accurate tumour staging, including assessment of lymph node status, a number of additional factors have previously been shown to influence selection of appropriate adjuvant therapy, including specialisation, caseload and a teaching hospital setting [7, 8, 17] . These factors however should now be much less relevant with the introduction of breast surgery as a surgical speciality and multidisciplinary team decision making.
The availability of ER status also significantly influences the choice of adjuvant systemic therapy [18] and a postal survey published in 1998 found that only 84% of breast units in the UK had access to ER measurement, with only 60% on site [19] . An updated survey, published near the end of the study period for this paper, showed that although access to measurement had improved, there was considerable variability in both the specific technique of ER measurement and the absolute cut-off point for positivity (5%-80%) [20] . Multivariate survival analysis indicates that the differences between hospitals for women with 1-3 nodes positive in this study is mainly explained by differences between units in ER status as well as socio-economic status, measured by IMD. It is therefore noteworthy that this study has identified a group with ER status unknown during this time period (1999) (2000) (2001) (2002) (2003) and that this group has a significantly worse survival than ER-positive patients. As previously described, increased deprivation in this study is associated with increased hazard of dying from breast cancer [10] .
The fact that inter-hospital survival differences were significant for patients with 1-3 positive nodes indicates interhospital differences in the selection of appropriate adjuvant systemic therapy for this group. Quantitative decision support tools such as ADJUVANT! (www.adjuvantonline.com) [21] have been developed to estimate prognosis and absolute treatment benefits for an individual patient for both chemotherapy and hormone therapy. Although this more quantitative approach should allow greater consistency in prescription of chemotherapy, there is currently no international consensus on what should be the threshold benefit for recommending chemotherapy. 
